Lund, Sweden — 6 September 2022 — Camurus (NASDAQ STO: CAMX) is today hosting a Capital Markets and R&D Day at 1.00 pm CET, IVA Conference Center, Grev Turegatan 16, Stockholm. Presentations from senior management includes an updated five-year vision for growth and sustainable value creation for stakeholders within the core areas of CNS and rare diseases. The revenue ambition for 2027 will be communicated as per below.
“Camurus has had a strong development and financial performance over the past years and is well positioned to continue deliver significant growth and sustainable value creation”, says Fredrik Tiberg, President and CEO of Camurus. “Accordingly, our aspiration is to deliver 5-fold revenue growth over the next five years aiming at approximately 50 percent operating margin, driven by continued market penetration and expansion of our lead product, Buvidal®, taking late-stage pipeline programs to approval and launch, and globalizing our business.”
The presentations will be made available via link on Camurus’ website www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com
This information was submitted for publication at 08:30 am CET on 6 September 2022.